Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 56,53€(+706.525,00%). Der Median liegt bei 56,53€(+706.525,00%).
Kaufen | 7 |
Halten | 1 |
Verkaufen | 1 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 6 / 18 |
Levermann-Strategie | -6 / 13 |
News
Evofem's PHEXXI Submitted for Marketing Approval in United Arab Emirates by Pharma 1 Drug Store
— Pharma 1 Will Place Launch Quantity Order for PHEXXI in July 2025 — — Commercial Launch in UAE Targeted for Q1 2026 — SAN DIEGO , June 23, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM) announced today that private Emirati health care company Pharma 1 Drug Store LLC has filed an application with the United Arab Emirates (UAE) Ministry of Health and Prevention (MOHAP) seeking approval to commercialize PHEXXI® (lactic acid, citric acid, and potassium bitartrate) Evofem's FDA-approved hormone-free contraceptive, in the UAE. "With the submission to MOHAP now complete, we are developing our commercial strategy for PHEXXI in the UAE and look forward to launching this important product as quickly as possible following approval," said Abdulwahab Atfah, CEO of Pharma 1 Drug Store.» Mehr auf prnewswire.com
Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) (“Evofem”), to Aditxt's Board of Directors. “We believe that Saundra's background as a CEO and entrepreneur, coupled with her deep industry expertise and knowledge, will complement our current Board well. We look forward to her co.» Mehr auf businesswire.com
Evofem Signs SOLOSEC License Agreement for Middle East with Pharma 1
— Pharma 1 Targets Mid-2025 Regulatory Submission in UAE for SOLOSEC to Treat Bacterial Vaginosis and Trichomoniasis — SAN DIEGO , May 21, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM) and private Emirati health care company Pharma 1 Drug Store LLC have signed a License and Supply Agreement for the Middle East rights to SOLOSEC® (secnidazole) 2 g oral granules, Evofem's FDA-approved single-dose oral treatment for two common sexual health conditions. Consideration to Evofem for the exclusive commercial rights to SOLSOEC in the Territory includes an upfront payment, payments on achievement of certain regulatory milestones, and sales-based milestone payments.» Mehr auf prnewswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 781,08k | 76,60% |
Bruttoeinkommen | 443,69k | 83,60% |
Nettoeinkommen | 883,68k | 119,83% |
EBITDA | 513,94k | 119,92% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 906,82k€ |
Anzahl Aktien | 113,36 Mio |
52 Wochen-Hoch/Tief | 0,0137€ - 0,00512€ |
Dividenden | Nein |
Beta | -0,99 |
KGV (PE Ratio) | −0,34 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | −0,02 |
KUV (PS Ratio) | 0,07 |
Unternehmensprofil
Evofem Biosciences, Inc. ist ein biopharmazeutisches Unternehmen, das verschiedene Produkte entwickelt und vermarktet, um ungedeckte Bedürfnisse im Bereich der sexuellen und reproduktiven Gesundheit von Frauen zu erfüllen. Sein kommerzielles Produkt ist Phexxi, ein Vaginalgel zur Verhütung von Schwangerschaften. Das Unternehmen ist auch an der Entwicklung von EVO100 beteiligt, einem antimikrobiellen Vaginalgel zur Prävention der urogenitalen Übertragung von Chlamydia trachomatis und Neisseria gonorrhoeae bei Frauen. Der Hauptsitz von Evofem Biosciences, Inc. befindet sich in San Diego, Kalifornien.
Name | Evofem Biosciences |
CEO | Saundra Pelletier |
Sitz | San Diego, ca USA |
Website | |
Industrie | Biotechnologie |
Börsengang | |
Mitarbeiter | 32 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | EVFM |
Pnk | EVFM |
Assets entdecken
Shareholder von Evofem Biosciences investieren auch in folgende Assets